




**Fig. S1. Genotype assessment of the mouse model.** DNA extracted from the tail of WT STD (n = 3) and *ApoE*<sup>-/-</sup> (n = 10) mice was used to perform the genetic characterization through PCR analysis. bp: Base pairs.




**Fig. S2. Histopathological analysis of NAFLD progression.** (A) The quantification of steatosis, inflammation and ballooning in WT STD (n = 4-5), *ApoE*<sup>-/-</sup> STD (n = 5-7) and *ApoE*<sup>-/-</sup> HFD (n = 8-10) mice after 8 (*left*) or 18 (*right*) weeks on diet. (B) mRNA levels of *Ccl2* by RT-qPCR in livers from WT STD (n = 5), *ApoE*<sup>-/-</sup> STD (n = 8) and *ApoE*<sup>-/-</sup> HFD (n = 11) mice fed on 18 weeks. *Gapdh* was used as a control. (C) Measurement of lipid droplet size (μm<sup>2</sup>) in WT STD (n = 5-6), *ApoE*<sup>-/-</sup> STD (n = 3-6) and *ApoE*<sup>-/-</sup> HFD (n = 8-9) mice fed for 8 or 18 weeks. (D) Representative images of Sirius Red staining to study hepatic fibrosis (image magnification: x10) and the quantification of positive area staining and fibrosis score in WT STD (n = 4), *ApoE*<sup>-/-</sup> STD (n = 4) and *ApoE*<sup>-/-</sup> HFD (n = 6-12) mice after 18 weeks on diet. Results are expressed as mean ± SEM. Statistical significance was assessed by two-tailed unpaired Student's *t*-test with the exception of Sirius Red positive area and fibrosis score data which were evaluated by unpaired non-parametric Mann-Whitney U test and it was represented as \* (p < 0.05), \*\* (p < 0.01) and \*\*\* (p < 0.001) vs. WT STD mice; \$ (p < 0.05), \$\$ (p < 0.01) and \$\$\$ (p < 0.001) vs. *ApoE*<sup>-/-</sup> STD mice.



**Fig. S3. Glucose tolerance is also altered in mice with liver injury.** GTT in WT STD (n = 7), *Apoe*<sup>-/-</sup> STD (n = 5-6) and *Apoe*<sup>-/-</sup> HFD (n = 7) animals after 17 weeks on diet. Results are expressed as mean ± SEM. Statistical significance was assessed by two-tailed unpaired Student's *t*-test and it was represented as \* (p < 0.05), \*\* (p < 0.01) and \*\*\* (p < 0.001) vs. WT STD mice; \$\$ (p < 0.01) and \$\$\$ (p < 0.001) vs. *Apoe*<sup>-/-</sup> STD mice.




**Fig. S4. miRNA expression study through RT-qPCR in the liver.** Level comparison of: (A) let-7d-5p, (B) miR-15b-5p, (C) miR-22-3p, (D) miR-27b-3p (E) miR-122-5p, (F) miR-146b-5p, (G) miR-181b-5p, (H) miR-192-5p and (I) miR-194-5p in livers from WT STD (n = 5-7), *Apoe*<sup>-/-</sup> STD (n = 4-9) and *Apoe*<sup>-/-</sup> HFD (n = 6-10) mice fed 8 or 18 weeks on diet. miR-191-5p was used as a control. Results are expressed as mean  $\pm$  SEM. Normality test determined 8-week of diet data as normal, except for RQ let-7d-5p, and 18-week of diet data as no normal with the exception of RQ let-7d-5p, miR-15b-5p, miR-22-3p, miR-181b-5p and miR-194-5p. For that reason, statistical significance was assessed by two-tailed unpaired Student's *t*-test in the case of normal data and no normal data were evaluated by unpaired non-parametric Mann-Whitney U test, and it was represented as \* ( $p < 0.05$ ), \*\* ( $p < 0.01$ ) and \*\*\* ( $p < 0.001$ ) vs. WT STD mice; \$ ( $p < 0.05$ ), \$\$ ( $p < 0.01$ ) and \$\$\$ ( $p < 0.001$ ) vs. *Apoe*<sup>-/-</sup> STD mice.




**Fig. S5. *In vitro* overexpression of miR-26b-5p and miR-34a-5p induces the downregulation of some of their predicted targets.**

(A) Representative gels of western blot analysis of mTOR, FAS, SIRT1 and MFN2 in Huh7 cell lysates after miR-26b-5p and miR-34a-5p overexpression.  $\beta$ -actin was used as a loading control. (B) Histograms showing the protein/ $\beta$ -actin ratio quantification of band intensities in Control and transfected cells (Pre-miR-26b-5p and Pre-miR-34a-5p). At least, three technical replicates were performed. Results are expressed as mean  $\pm$  SEM. Statistical significance was assessed by two-tailed unpaired Student's t-test with the exception of mTOR and FAS data which were evaluated by unpaired non-parametric Mann-Whitney U test and it was represented as \*\* ( $p < 0.01$ ) and \*\*\* ( $p < 0.001$ ) vs. Control cells.





**Fig. S6. Summary of miRNA-target interactions involved in NAFLD progression.** The diagram displays the potential interactions of miR-26b-5p, miR-34a-5p, miR-149-5p and miR-375-5p with their targets regarding lipid metabolism, insulin signaling and autophagy.



**Fig. S7. Schematic representation of the main features of NAFLD in the *ApoE*<sup>-/-</sup> mouse model.** This graph highlights the noticeable histological differences between experimental groups and the selected miRNAs as regulators of disease development and potential biomarkers for its diagnosis.

**Table S1. RT-qPCR primers sequence for gene expression.** Fwd.: Forward; Rev.: Reverse.

<b>Target gene</b>	<b>Primer sequence</b>
<b><i>Acaca</i> (NM_133360.2)</b>	Fwd.: 5'-GAATCTCCTGGTGACAATGCTTATT-3' Rev.: 5'-GGTCTTGCTGAGTTGGGTTAGCT-3'
<b><i>Actb</i> (NM_007393)</b>	Fwd.: 5'-GACATGGAGAAGATCTGGCA-3' Rev.: 5'-GGTCTCAAACATGATCTGGGT-3'
<b><i>Adipor2</i> (NM_197985.4)</b>	Fwd.: 5'-TCTCAGTGGGACATGTTTGC-3' Rev.: 5'-AGGCCTAAGCCCACGAAC-3'
<b><i>Cd36</i> (NM_001159555.1)</b>	Fwd.: 5'-AGATGACGTGGCAAAGAACAG-3' Rev.: 5'-CCTTGGCTAGATAACGAACTCTG-3'
<b><i>Fasn</i> (NM_007988.3)</b>	Fwd.: 5'-TCGGCGGGTCTATGCCACGA-3' Rev.: 5'-GTCACCCACCTTGGTGCCCG-3'
<b><i>Ppargc1a</i> (NM_008904.2)</b>	Fwd.: 5'-TCGCTGATGCACTGCCTATG-3' Rev.: 5'-GAGAGGTCCACAGAGCTGATT-3'
<b><i>Scd1</i> (NM_009127.4)</b>	Fwd.: 5'-TTCTTGCGATACTCTGGTGC-3' Rev.: 5'-CGGGATTGAATGTTCTTGTCGT-3'
<b><i>Srebf1</i> (NM_001358314.1)</b>	Fwd.: 5'-CACTGGTCGTAGATGCGGAGAA-3' Rev.: 5'-TCATTGATGGAGGAGCGGTAGC-3'

**Table S2. TaqMan probes used for RT-qPCR analyses.**

Target gene	Reference
<i>Ccl2</i>	Mm00441242_m1
<i>Gapdh</i>	Mm03302249_g1
mmu-let-7d-5p	mmu478439_mir
mmu-miR-15b-5p	mmu482957_mir
mmu-miR-16b-5p	mmu482960_mir
mmu-miR-22-3p	mmu481004_mir
mmu-miR-26b-5p	mmu482965_mir
mmu-miR-27b-3p	mmu478270_mir
mmu-miR-34a-5p	mmu481304_mir
mmu-miR-122-5p	mmu480899_mir
mmu-miR-146b-5p	mmu478513_mir
mmu-miR-149-5p	mmu480946_mir
mmu-miR-181b-5p	mmu478583_mir
mmu-miR-191-5p	mmu481584_mir
mmu-miR-192-5p	mmu480876_mir
mmu-miR-194-5p	mmu480976_mir
mmu-miR-375-5p	mmu481141_mir

**Table S3. List of primary antibodies used for Western blot analysis.**

Antibody	Host	Dilution	Reference	Supplier	
CD63 (EPR5702)	Rabbit	1:1000	ab134045	Abcam (Cambridge, UK)	
MFN2	Mouse	1:1000 (liver extracts) // 1:5000 (cell lysates)	ab56889		
ACC	Rabbit	1:1000	#3662	Cell Signaling Technology (Danvers, MA, USA)	
AKT	Rabbit	1:1000	#9272		
CD81 (D502Q)	Rabbit	1:1000	#10037		
FAS	Rabbit	1:1000 (liver extracts) // 1:5000 (cell lysates)	#3180		
GM130 (D6B1)	Rabbit	1:1000	#12480		
mTOR (7C10)	Rabbit	1:1000	#2983		
LC3A/B	Rabbit	1:1000	#4108		
p-AKT (Ser473) (193H12)	Rabbit	1:1000	#4058		
p-AKT (Thr308) (D25E6)	Rabbit	1:1000	#9275		
p-ULK1 (Ser757) (D70U6)	Rabbit	1:1000	#1402		
PKC $\epsilon$ (22B10)	Rabbit	1:1000	#2683		
SCD1 (C12H5)	Rabbit	1:1000	#2794		
PI3 Kinase p85 $\alpha$	Rabbit	1:1000	ABS234		Merck Millipore (Burlington, MA, USA)
SIRT1	Rabbit	1:1000 (liver extracts) // 1:2000 (cell lysates)	#07-131		
IR $\beta$ (C-19)	Rabbit	1:1000	sc-711	Santa Cruz Biotechnology (Dallas, TX, USA)	
$\alpha$ -tubulin (DM1A)	Mouse	1:1000	T6199	Sigma-Aldrich (St. Louis, MO, USA)	
$\beta$ -actin	Mouse	1:5000 (liver extracts) // 1:10000 (cell lysates)	A5441		